Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077662 · ClinicalTrials.gov registry record
A Prospective, Observational Study in Patients With Late-Onset Pompe Disease
A clinical trial, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 61
- Enrollment target
NCT00077662 is a clinical trial that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 61 participants.
The verdict
NCT00077662 has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 61 participants
- Enrollment target
Study Summary
Pompe disease (also known as glycogen storage disease type II, "GSD-II") is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. This study is being conducted to collect prospective, observational data on patients with late-onset Pompe disease. Approximately 60 subjects with late-onset Pompe disease will be enrolled.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077662
The ClinicalTrials.gov registry entry for NCT00077662 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00077662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077662 about?
NCT00077662 is a clinical study titled "A Prospective, Observational Study in Patients With Late-Onset Pompe Disease". Pompe disease (also known as glycogen storage disease type II, "GSD-II") is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lyso...
What is the current status of trial NCT00077662?
This trial is currently completed. The enrollment target is 61 participants. The study started on 2004-03. Estimated completion is 2006-01.
Who is sponsoring clinical trial NCT00077662?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.